α 4 β 7 Integrin Antagonist Vedolizumab for the Treatment of Refractory Ileitis
- PMID: 31143480
- PMCID: PMC6501135
- DOI: 10.1155/2019/2091089
α 4 β 7 Integrin Antagonist Vedolizumab for the Treatment of Refractory Ileitis
Abstract
Background and aims: Ulcerative colitis (UC) is a superficial diffuse inflammation restricted to the colon and rectum. Inflammation within the small bowel may occur several years after a pancolectomy. The pathogenesis is unknown and seems to be different from Crohn's disease or other causes of diseases of the small intestine, but an association with colectomy due to UC is very likely.
Methods and results: We describe the case of a patient with a probable diagnosis of pan-UC accompanied by Sjögren's syndrome and partial IgA deficiency, who developed enteritis after a restorative pancolectomy. For induction and maintenance of remission, the patient was successfully treated with mycofenolate mofetil (MMF) and vedolizumab (VDZ).
Conclusions: We suggest that a previously refractory to standard therapy UC-related enteritis can be treated with combination MMF and VDZ.
Figures



Similar articles
-
Vedolizumab, an option in patients with inflammatory bowel disease intolerant to thiopurines and refractory to biological agents.Gastroenterol Hepatol. 2018 Nov;41(9):535-543. doi: 10.1016/j.gastrohep.2018.06.001. Epub 2018 Jul 19. Gastroenterol Hepatol. 2018. PMID: 30031573 English, Spanish.
-
Vedolizumab for ulcerative colitis and Crohn's disease: results and implications of GEMINI studies.Immunotherapy. 2014;6(9):963-71. doi: 10.2217/imt.14.66. Immunotherapy. 2014. PMID: 25341118 Clinical Trial.
-
Effects of Anti-Integrin Treatment With Vedolizumab on Immune Pathways and Cytokines in Inflammatory Bowel Diseases.Front Immunol. 2018 Jul 31;9:1700. doi: 10.3389/fimmu.2018.01700. eCollection 2018. Front Immunol. 2018. PMID: 30131801 Free PMC article.
-
Introducing vedolizumab to clinical practice: who, when, and how?J Crohns Colitis. 2015 Apr;9(4):356-66. doi: 10.1093/ecco-jcc/jjv033. Epub 2015 Feb 16. J Crohns Colitis. 2015. PMID: 25687206 Review.
-
Vedolizumab: an α4β7 integrin antagonist for ulcerative colitis and Crohn's disease.Ther Adv Chronic Dis. 2015 Sep;6(5):224-33. doi: 10.1177/2040622315586970. Ther Adv Chronic Dis. 2015. PMID: 26336591 Free PMC article. Review.
References
-
- Mukewar S., Wu X., Lopez R., Shen B. Comparison of long-term outcomes of S and J pouches and continent ileostomies in ulcerative colitis patients with restorative proctocolectomy-experience in subspecialty pouch center. Journal of Crohn's and Colitis. 2014;8(10):1227–1236. doi: 10.1016/j.crohns.2014.02.019. - DOI - PubMed
-
- Bell A. J., Price A. B., Forbes A., Ciclitira P. J., Groves C., Nicholls R. J. Pre-pouch ileitis: A disease of the ileum in ulcerative colitis after restorative proctocolectomy. Colorectal Disease. 2006;8(5):402–410. doi: 10.1016/j.ydbio.2006.04.233. doi: 10.1111/j.1463-1318.2006.00954.x. - DOI - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous